Biomarkers in Obesity: Serum Myeloperoxidase and Traditional Cardiac Risk Parameters

Experimental and Clinical Endocrinology and Diabetes

Volumn 124, Issue 1, 2016, Pages 49-54

  Borato, D C K ^a   Parabocz, G C ^a   Ribas, J T ^a   Netto, H P ^a   Erdmann, F C ^a   Wiecheteck, L D ^a   Manente, F A ^a   De Almeida Mello, L R ^a   Bello C ^a   Andre Dos Santos F ^a   Borba, L M ^a   Vellosa, J C R ^a  

^a STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

Author keywords

cardiovascular risk; inflammation; myeloperoxidase; obesity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; MYELOPEROXIDASE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; PEROXIDASE;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; ENZYME BLOOD LEVEL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INFLAMMATION; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL COUNT; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; OBESITY; PEROXIDASE; RISK FACTORS;

EID: 84955308912     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0035-1565093     Document Type: Article

References (41)

1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol: 2005; 115 911 919
2. Berg A. H., Scherer P. E. Adipose tissue, inflammation, and cardiovascular disease. Circulation research: 2005; 96 939 949
3. Gregor M. F., Hotamisligil G. S. Inflammatory mechanisms in obesity. Annu Rev Immunol: 2011; 29 415 445
4. Roos C. J., Quax P. H., Jukema J. W. Cardiovascular metabolic syndrome: Mediators involved in the pathophysiology from obesity to coronary heart disease. Biomark Med: 2012; 6 35 52
5. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). Jama: 2001; 285 2486 2497
6. Vachharajani V., Granger D. N. Adipose tissue: A motor for the inflammation associated with obesity. IUBMB life: 2009; 61 424 430
7. Saito M., Ishimitsu T., Minami J. et al. Relations of plasma high-sensitivity c-reactive protein to traditional cardiovascular risk factors. Atherosclerosis: 2003; 167 73 79
8. Nicholls S. J., Hazen S. L. Myeloperoxidase and cardiovascular disease. Arterosclorer Thromb Vasc Biol: 2005; 25 1102 1111
9. Zhang R., Brennan M. L., Fu X. et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama: 2001; 286 2136 2142
10. Baldus S., Heeschen C., Meinertz T. et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation: 2003; 108 1440 1445
11. Meuwese M. C., Stroes E. S., Hazen S. L. et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The epic-norfolk prospective population study. J Am Coll Cardiol: 2007; 50 159 165
12. Wu A. H. Early detection of acute coronary syndromes and risk stratification by multimarker analysis. Biomark Med: 2007; 1 45 57
13. Rudolph V., Goldmann B. U., Bos C. et al. Diagnostic value of mpo plasma levels in patients admitted for suspected myocardial infarction. Inter J Cardiol: 2011; 153 267 271
14. Borato D. C., Parabocz G. C., Ribas S. R. et al. Changes of metabolic and inflammatory markers in hiv infection: Glucose, lipids, serum hs-crp and myeloperoxidase. Metab Clin Exp: 2012; 61 1353 1360
15. Zur B., Look M., Holdenrieder S. et al. Elevated plasma myeloperoxidase concentration in adults with obesity. Clin Chim Acta: 2011; 412 1891 1892
16. Andrade V. L., Petruceli E., Belo V. A. et al. Evaluation of plasmatic mmp-8, mmp-9, timp-1 and mpo levels in obese and lean women. Clin Biochemistry: 2012; 45 412 415
17. Musaad S., Haynes E. N. Biomarkers of obesity and subsequent cardiovascular events. Epidemiol Rev: 2007; 29 98 114
18. WHO Obesity: Preventing and managing the global epidemic. Report of a who consultation. World Health Organization technical report series: 2000; 894 i-xii 1 253
19. Vita J. A., Brennan M. L., Gokce N. et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation: 2004; 110 1134 1139
20. Samsamshariat S. Z., Basati G., Movahedian A. et al. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease. Biomark Med: 2011; 5 377 385
21. Roman R. M., Camargo P. V., Borges F. K. et al. Prognostic value of myeloperoxidase in coronary artery disease: Comparison of unstable and stable angina patients. J Coron Artery Dis: 2010; 21 129 136
22. Kutter D., Devaquet P., Vanderstocken G. et al. Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? Acta haematol: 2000; 104 10 15
23. Asselbergs F. W., Reynolds W. F., Cohen-Tervaert J. W. et al. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med: 2004; 116 429 430
24. Nikpoor B., Turecki G., Fournier C. et al. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in french-canadians. Am Heart J: 2001; 142 336 339
25. Olza J., Aguilera C. M., Gil-Campos M. et al. Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children. Diabetes care: 2012; 35 2373 2376
26. Howard B. V., Ruotolo G., Robbins D. C. Obesity and dyslipidemia. Endocrinol Metab Clin North Am: 2003; 32 855 867
27. Klop B., Elte J. W., Cabezas M. C. Dyslipidemia in obesity: Mechanisms and potential targets. Nutrients: 2013; 5 1218 1240
28. Dullaart R. P., Annema W., Tio R. A. et al. The hdl anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of hdl cholesterol. Clin Chim Acta: 2014; 433 34 38
29. van Deventer H. E., Miller W. G., Myers G. L. et al. Non-hdl cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated ldl cholesterol in a dyslipidemic population. Clin Chem: 2011; 57 490 501
30. Nicholls S. J., Hazen S. L. Myeloperoxidase modified lipoproteins, and atherogenesis. J Lip Res: 2009; 50 Suppl S346 S351
31. Ostfeld R., Mookherjee D., Spinelli M. et al. A triglyceride/high-density lipoprotein ratio>or=3.5 is associated with an increased burden of coronary artery disease on cardiac catheterization. J Cardiometabolic Syndr: 2006; 1 13 15
32. Salazar M. R., Carbajal H. A., Espeche W. G. et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am Journal Cardiology: 2012; 109 1749 1753
33. Murguia-Romero M., Jimenez-Flores J. R., Sigrist-Flores S. C. et al. Plasma triglyceride/hdl-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J Lipid Res: 2013; 54 2795 2799
34. Hanak V., Munoz J., Teague J. et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype b. Am Journal Cardiology: 2004; 94 219 222
35. Gaziano J. M., Hennekens C. H., O'Donnell C. J. et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation: 1997; 96 2520 2525
36. Bittner V., Johnson B. D., Zineh I. et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A report from the women's ischemia syndrome evaluation (wise). Am Heart J: 2009; 157 548 555
37. Jeppesen J., Hein H. O., Suadicani P. et al. Relation of high tg-low hdl cholesterol and ldl cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the copenhagen male study. Arterioscler Thromb Vasc Biol: 1997; 17 1114 1120
38. Esser N., Legrand-Poels S., Piette J. et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Prac: 2014; 105 141 150
39. Mathew M., Tay E., Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and pai-1 in healthy subjects. Cardiovascular diabetology: 2010; 9 9
40. Wang Q., Xie Z., Zhang W. et al. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes: 2014; 63 4172 4185
41. Nijhuis J., Rensen S. S., Slaats Y. et al. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring, Md): 2009; 17 2014 2018